Hospital
Aurora Health Care Southern Lakes, INC.
Aurora Health Care Southern Lakes, INC. was paid $5.25M by Medicaid between Jan 2018 and Dec 2024, across 170 billing codes. Its largest line is 99283, emergency room visit (moderate) — 10.0% of everything it billed.
33Billing provider infoAURORA HEALTH CARE SOUTHERN LAKES, INC.
BURLINGTON, WI 53105
BURLINGTON, WI 53105
33aNPI1861557753assigned 12/22/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$5.25M
24GClaims253,744
24DCodes billed170
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Wisconsin
Rank by total paid#24 of 60
Median peer was paid$2.90M
This provider vs. median1.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official RICHARDSON, KARA controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 39,099 | $797K | |
| 2019 | 36,785 | $741K | |
| 2020 | 32,295 | $631K | |
| 2021 | 40,689 | $817K | |
| 2022 | 37,173 | $750K | |
| 2023 | 39,598 | $844K | |
| 2024incomplete | 28,105 | $672K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 10.0% | 8,826 | 7,959 | $523K |
| 96361 | Intravenous infusion, hydration; each additional hour | 9.2% | 3,788 | 3,181 | $484K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 9.1% | 14,366 | 4,925 | $480K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 7.5% | 7,742 | 6,877 | $396K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.0% | 5,068 | 4,448 | $264K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.0% | 2,759 | 2,527 | $211K |
| 80053 | Comprehensive metabolic panel | 3.8% | 11,154 | 9,139 | $201K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 3.6% | 930 | 881 | $190K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 3.5% | 8,608 | 3,166 | $186K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.2% | 2,560 | 2,339 | $169K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.6% | 2,204 | 2,031 | $135K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.9% | 1,798 | 1,556 | $100K |
158 more codes
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.8% | 4,302 | $94K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 1.8% | 483 | $92K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.7% | 918 | $90K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.5% | 13,423 | $80K |
| 97161 | 1.5% | 1,933 | $79K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.5% | 1,267 | $78K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.4% | 1,752 | $73K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | 1.3% | 281 | $71K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.1% | 558 | $56K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,009 | $52K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,330 | $52K |
| 84484 | <1% | 4,743 | $48K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 536 | $39K |
| 76642 | <1% | 1,154 | $39K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,531 | $38K |
| 84145 | <1% | 2,125 | $37K | |
| 64493 | <1% | 184 | $36K | |
| 83605 | <1% | 3,818 | $34K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,219 | $32K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 534 | $32K |
| 82077 | <1% | 1,345 | $32K | |
| 83880 | <1% | 958 | $31K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 432 | $30K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 412 | $30K |
| 64494 | <1% | 200 | $28K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 530 | $27K |
| 64483 | <1% | 151 | $26K | |
| 81025 | <1% | 2,938 | $25K | |
| 83735 | <1% | 5,000 | $24K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 633 | $24K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,340 | $24K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 646 | $23K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 568 | $23K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 191 | $21K |
| 83690 | <1% | 3,607 | $20K | |
| 82962 | <1% | 3,474 | $19K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 388 | $19K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 2,479 | $18K |
| 76830 | Ultrasound, transvaginal | <1% | 497 | $17K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 387 | $15K |
| 93356 | <1% | 155 | $15K | |
| 85610 | <1% | 3,379 | $14K | |
| 81001 | <1% | 4,194 | $13K | |
| 87040 | <1% | 1,059 | $12K | |
| 97162 | <1% | 360 | $12K | |
| 85379 | <1% | 1,419 | $11K | |
| G0378 | Hospital observation service, per hour | <1% | 905 | $9K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 108 | $9K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 151 | $9K |
| 62323 | <1% | 53 | $9K | |
| 81003 | <1% | 2,030 | $9K | |
| 84703 | <1% | 921 | $9K | |
| 80143 | <1% | 689 | $8K | |
| 80179 | <1% | 674 | $8K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 118 | $7K |
| 85730 | <1% | 1,530 | $7K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 311 | $7K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 44 | $7K |
| 97035 | <1% | 564 | $7K | |
| 93975 | <1% | 201 | $6K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 540 | $6K |
| 97597 | <1% | 161 | $5K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 71 | $5K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 43 | $5K |
| 64635 | <1% | 39 | $5K | |
| 64495 | <1% | 30 | $5K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 6,967 | $5K |
| 93971 | <1% | 129 | $5K | |
| 87081 | <1% | 146 | $4K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 371 | $4K |
| 0240U | <1% | 146 | $4K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 3,540 | $4K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 83 | $4K |
| 64636 | <1% | 51 | $4K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 201 | $4K |
| 71250 | <1% | 117 | $3K | |
| 82565 | <1% | 215 | $3K | |
| 97113 | <1% | 49 | $3K | |
| 77066 | Tomosynthesis, mammo | <1% | 192 | $2K |
| 87186 | <1% | 262 | $2K | |
| 71045 | Radiologic examination, chest; single view | <1% | 4,068 | $1K |
| 97165 | <1% | 45 | $1K | |
| 94729 | <1% | 62 | $1K | |
| 77062 | <1% | 108 | $1K | |
| 77065 | Tomosynthesis, mammo | <1% | 116 | $1K |
| 97116 | <1% | 92 | $975.13 | |
| 72141 | <1% | 13 | $945.94 | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 962 | $789.17 |
| 85027 | <1% | 186 | $788.22 | |
| 80076 | <1% | 96 | $772.29 | |
| 87077 | <1% | 108 | $680.48 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,708 | $651.19 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,575 | $615.44 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 56 | $609.00 |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 441 | $492.86 |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 317 | $491.20 |
| 94726 | <1% | 73 | $403.65 | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,151 | $384.08 |
| 86900 | <1% | 13 | $349.25 | |
| 94060 | <1% | 30 | $347.59 | |
| 77061 | <1% | 62 | $332.38 | |
| J2704 | Injection, propofol, 10 mg | <1% | 5,363 | $307.02 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,737 | $297.56 |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | <1% | 1,608 | $268.55 |
| 80047 | <1% | 15 | $130.79 | |
| 82728 | <1% | 13 | $129.42 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 7,162 | $118.31 |
| 87070 | <1% | 19 | $110.47 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 5,947 | $82.29 |
| 87205 | <1% | 33 | $81.96 | |
| 86140 | <1% | 19 | $81.27 | |
| 90715 | <1% | 15 | $65.50 | |
| 83615 | <1% | 16 | $63.59 | |
| 84100 | <1% | 20 | $58.80 | |
| 86901 | <1% | 13 | $31.25 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 6,477 | $16.25 |
| 96376 | <1% | 621 | $10.68 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 5,821 | $7.32 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,627 | $5.08 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,644 | $3.66 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 897 | $2.57 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,410 | $1.84 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,308 | $1.26 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,864 | $0.92 |
| 36415 | Collection of venous blood by venipuncture | <1% | 2,331 | $0.84 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 1,878 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 1,055 | $0.00 |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 0% | 141 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 1,655 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 58 | $0.00 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 667 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 14 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 300 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 120 | $0.00 |
| A4565 | Slings | 0% | 12 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 102 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 15 | $0.00 |
| 73610 | 0% | 14 | $0.00 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 14 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 17 | $0.00 |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 58 | $0.00 |
| C1729 | Catheter, drainage | 0% | 20 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 15 | $0.00 |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 1,054 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 134 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 1,155 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 231 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 12 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 114 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 145 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 464 | $0.00 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 0% | 222 | $0.00 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 256 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 46 | $0.00 |
| C1769 | Guide wire | 0% | 138 | $0.00 |
| J7999 | Compounded drug, not otherwise classified | 0% | 14 | $0.00 |
| 80320 | 0% | 33 | $0.00 | |
| 88342 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRICHARDSON, KARA (VP MANAGED HEALTH)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.